Cefiderocol, a new drug that can attack several multi-drug resistant pathogens, is showing promise.
A new drug that can attack several multi-drug resistant pathogens is showing promise.
Investigational antibiotic cefiderocol (S-649266/Shionogi) showed it was effective against Gram-negative pathogens. Those included carbapenem-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae (photo), according to results presented Oct. 26 at IDWeek 2016 in New Orleans, LA.
Cefiderocol is a siderophore cephalosporin that uses a “Trojan horse” strategy to getting bacterial cells. Its binds to free iron and is then actively transported through these cells’ outer membrane. It is being studied for use in patients with complicated urinary tract infections and in patients with carbapenem-resistant pathogens at various infection sites.
The results presented at the conference were from in vitro data from 8,765 test strains of those pathogens from patients in North American and Europe in 2014-2015.
Among the key findings, according to the company: